ANXU.L vs. NVO

Last updated Jun 13, 2026

ANXU.L (Amundi Nasdaq-100 UCITS USD) is Nasdaq-100 fund tracking the Russell 1000 Growth TR USD, while NVO (Novo Nordisk A/S) is a stock. Over the past 10 years, ANXU.L returned 21.68%/yr vs 7.56%/yr for NVO. At a 0.29 correlation, their price movements are largely independent.

Performance

ANXU.L vs. NVO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Amundi Nasdaq-100 UCITS USD (ANXU.L) and Novo Nordisk A/S (NVO). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, ANXU.L achieves a 16.81% return, which is significantly higher than NVO's -10.74% return. Over the past 10 years, ANXU.L has outperformed NVO with an annualized return of 21.68%, while NVO has yielded a comparatively lower 7.56% annualized return.

ANXU.L

• 1D: 3.02%
• 1M: 0.06%
• YTD: 16.81%
• 6M: 18.06%
• 1Y: 36.71%
• 3Y*: 26.40%
• 5Y*: 16.87%
• 10Y*: 21.68%

NVO

• 1D: -0.18%
• 1M: -4.19%
• YTD: -10.74%
• 6M: -9.50%
• 1Y: -42.47%
• 3Y*: -15.59%
• 5Y*: 2.92%
• 10Y*: 7.56%

*Multi-year figures are annualized to reflect compound growth (CAGR)

ANXU.L vs. NVO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ANXU.L Amundi Nasdaq-100 UCITS USD	16.81%	19.86%	26.74%	56.50%	-33.24%	27.99%	48.47%	39.48%	-1.06%	32.58%
NVO Novo Nordisk A/S	-10.74%	-39.22%	-15.93%	54.84%	22.66%	63.52%	23.33%	28.70%	-12.98%	52.92%

Correlation

The correlation between ANXU.L and NVO is 0.21, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.21
Correlation (3Y) Calculated over the trailing 3-year period	0.14
Correlation (5Y) Calculated over the trailing 5-year period	0.15
Correlation (10Y) Calculated over the trailing 10-year period	0.21
Correlation (All Time) Calculated using the full available price history since Jul 2, 2010	0.29

The correlation between ANXU.L and NVO shifts across timeframes, from 0.14 (3 years) to 0.29 (all time), reflecting how their relationship changes across market environments.

Return for Risk

ANXU.L vs. NVO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ANXU.L

ANXU.L Risk / Return Rank: 74
ANXU.L Sharpe Ratio Rank: 78
ANXU.L Sortino Ratio Rank: 78
ANXU.L Omega Ratio Rank: 73
ANXU.L Calmar Ratio Rank: 73
ANXU.L Martin Ratio Rank: 70

NVO

NVO Risk / Return Rank: 12
NVO Sharpe Ratio Rank: 9
NVO Sortino Ratio Rank: 12
NVO Omega Ratio Rank: 10
NVO Calmar Ratio Rank: 12
NVO Martin Ratio Rank: 16

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ANXU.L vs. NVO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Amundi Nasdaq-100 UCITS USD (ANXU.L) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	ANXU.L	NVO	Difference
Sharpe ratio: Return per unit of total volatility	2.16	-0.84	+3.00
Sortino ratio: Return per unit of downside risk	3.01	-1.05	+4.06
Omega ratio: Gain probability vs. loss probability	1.37	0.85	+0.52
Calmar ratio: Return relative to maximum drawdown	3.25	-0.80	+4.05
Martin ratio: Return relative to average drawdown	11.32	-1.18	+12.50

ANXU.L vs. NVO - Sharpe Ratio Comparison

The current ANXU.L Sharpe Ratio is 2.16, which is higher than the NVO Sharpe Ratio of -0.84. The chart below compares the historical Sharpe Ratios of ANXU.L and NVO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

ANXU.L vs. NVO - Drawdown Comparison

The maximum ANXU.L drawdown since its inception was -35.13%, smaller than the maximum NVO drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for ANXU.L and NVO.

Drawdown Indicators

	ANXU.L	NVO	Difference
Max Drawdown Largest peak-to-trough decline	-35.13%	-74.70%	+39.57%
Max Drawdown (1Y) Largest decline over 1 year	-11.01%	-54.34%	+43.33%
Max Drawdown (3Y) Largest decline over 3 years	-22.45%	-74.70%	+52.25%
Max Drawdown (5Y) Largest decline over 5 years	-35.13%	-74.70%	+39.57%
Max Drawdown (10Y) Largest decline over 10 years	-35.13%	-74.70%	+39.57%
Current Drawdown Current decline from peak	-3.14%	-68.11%	+64.97%
Average Drawdown Average peak-to-trough decline	-5.05%	-17.79%	+12.74%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.16%	37.62%	-34.46%

Volatility

ANXU.L vs. NVO - Volatility Comparison

The current volatility for Amundi Nasdaq-100 UCITS USD (ANXU.L) is 6.29%, while Novo Nordisk A/S (NVO) has a volatility of 10.68%. This indicates that ANXU.L experiences smaller price fluctuations and is considered to be less risky than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ANXU.L	NVO	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.29%	10.68%	-4.39%
Volatility (6M) Calculated over the trailing 6-month period	12.80%	38.04%	-25.24%
Volatility (1Y) Calculated over the trailing 1-year period	16.52%	51.88%	-35.36%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	20.84%	38.33%	-17.49%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	20.12%	32.56%	-12.44%

Dividends

ANXU.L vs. NVO - Dividend Comparison

ANXU.L has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 4.11%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
ANXU.L Amundi Nasdaq-100 UCITS USD	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NVO Novo Nordisk A/S	4.11%	3.31%	1.68%	1.00%	1.20%	1.35%	1.87%	2.14%	1.45%	1.52%	2.87%	0.92%

Frequently Asked Questions

Can I hold both ANXU.L and NVO in my portfolio?

ANXU.L and NVO have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.